Chambal Fertilisers & Chemicals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 7:49 am

Competitors of Chambal Fertilisers & Chemicals Ltd

All Competitor Stocks of Chambal Fertilisers & Chemicals Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:45 pm

Below is a detailed analysis of the quarterly data for Chambal Fertilisers & Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 5,698.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,449.00 Cr. (Mar 2025) to 5,698.00 Cr., marking an increase of 3,249.00 Cr..
• For Expenses, as of Jun 2025, the value is 4,937.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,285.00 Cr. (Mar 2025) to 4,937.00 Cr., marking an increase of 2,652.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 761.00 Cr.. The value appears strong and on an upward trend. It has increased from 163.00 Cr. (Mar 2025) to 761.00 Cr., marking an increase of 598.00 Cr..
• For OPM %, as of Jun 2025, the value is 13.00%. The value appears strong and on an upward trend. It has increased from 7.00% (Mar 2025) to 13.00%, marking an increase of 6.00%.
• For Other Income, as of Jun 2025, the value is 79.00 Cr.. The value appears to be declining and may need further review. It has decreased from 86.00 Cr. (Mar 2025) to 79.00 Cr., marking a decrease of 7.00 Cr..
• For Interest, as of Jun 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 84.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 82.00 Cr. (Mar 2025) to 84.00 Cr., marking an increase of 2.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 754.00 Cr.. The value appears strong and on an upward trend. It has increased from 168.00 Cr. (Mar 2025) to 754.00 Cr., marking an increase of 586.00 Cr..
• For Tax %, as of Jun 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Mar 2025) to 27.00%, marking an increase of 5.00%.
• For Net Profit, as of Jun 2025, the value is 549.00 Cr.. The value appears strong and on an upward trend. It has increased from 130.00 Cr. (Mar 2025) to 549.00 Cr., marking an increase of 419.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 13.70. The value appears strong and on an upward trend. It has increased from 3.25 (Mar 2025) to 13.70, marking an increase of 10.45.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:34 am

Growth

Last Updated: September 5, 2025, 1:50 am

Balance Sheet

Last Updated: November 9, 2025, 1:50 pm

Below is a detailed analysis of the balance sheet data for Chambal Fertilisers & Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 401.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 401.00 Cr..
• For Reserves, as of Sep 2025, the value is 9,438.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,327.00 Cr. (Mar 2025) to 9,438.00 Cr., marking an increase of 1,111.00 Cr..
• For Borrowings, as of Sep 2025, the value is 100.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 99.00 Cr. (Mar 2025) to 100.00 Cr., marking an increase of 1.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 3,914.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,580.00 Cr. (Mar 2025) to 3,914.00 Cr., marking an increase of 1,334.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 13,853.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,407.00 Cr. (Mar 2025) to 13,853.00 Cr., marking an increase of 2,446.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 6,090.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,221.00 Cr. (Mar 2025) to 6,090.00 Cr., marking a decrease of 131.00 Cr..
• For CWIP, as of Sep 2025, the value is 1,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 650.00 Cr. (Mar 2025) to 1,135.00 Cr., marking an increase of 485.00 Cr..
• For Investments, as of Sep 2025, the value is 952.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,372.00 Cr. (Mar 2025) to 952.00 Cr., marking a decrease of 420.00 Cr..
• For Other Assets, as of Sep 2025, the value is 5,676.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,164.00 Cr. (Mar 2025) to 5,676.00 Cr., marking an increase of 2,512.00 Cr..
• For Total Assets, as of Sep 2025, the value is 13,853.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,407.00 Cr. (Mar 2025) to 13,853.00 Cr., marking an increase of 2,446.00 Cr..

Notably, the Reserves (9,438.00 Cr.) exceed the Borrowings (100.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Chambal Fertilisers & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 41.17. This value is within the healthy range. It has increased from 30.84 (Mar 24) to 41.17, marking an increase of 10.33.
• For Diluted EPS (Rs.), as of Mar 25, the value is 41.17. This value is within the healthy range. It has increased from 30.84 (Mar 24) to 41.17, marking an increase of 10.33.
• For Cash EPS (Rs.), as of Mar 25, the value is 46.12. This value is within the healthy range. It has increased from 37.64 (Mar 24) to 46.12, marking an increase of 8.48.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 217.85. It has increased from 181.16 (Mar 24) to 217.85, marking an increase of 36.69.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 217.85. It has increased from 181.16 (Mar 24) to 217.85, marking an increase of 36.69.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 415.48. It has decreased from 448.43 (Mar 24) to 415.48, marking a decrease of 32.95.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 67.36. This value is within the healthy range. It has increased from 57.22 (Mar 24) to 67.36, marking an increase of 10.14.
• For PBIT / Share (Rs.), as of Mar 25, the value is 59.11. This value is within the healthy range. It has increased from 49.41 (Mar 24) to 59.11, marking an increase of 9.70.
• For PBT / Share (Rs.), as of Mar 25, the value is 57.91. This value is within the healthy range. It has increased from 45.09 (Mar 24) to 57.91, marking an increase of 12.82.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 37.88. This value is within the healthy range. It has increased from 29.83 (Mar 24) to 37.88, marking an increase of 8.05.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 41.17. This value is within the healthy range. It has increased from 31.84 (Mar 24) to 41.17, marking an increase of 9.33.
• For PBDIT Margin (%), as of Mar 25, the value is 16.21. This value is within the healthy range. It has increased from 12.75 (Mar 24) to 16.21, marking an increase of 3.46.
• For PBIT Margin (%), as of Mar 25, the value is 14.22. This value is within the healthy range. It has increased from 11.01 (Mar 24) to 14.22, marking an increase of 3.21.
• For PBT Margin (%), as of Mar 25, the value is 13.93. This value is within the healthy range. It has increased from 10.05 (Mar 24) to 13.93, marking an increase of 3.88.
• For Net Profit Margin (%), as of Mar 25, the value is 9.11. This value is within the healthy range. It has increased from 6.65 (Mar 24) to 9.11, marking an increase of 2.46.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.90. This value is within the healthy range. It has increased from 7.10 (Mar 24) to 9.90, marking an increase of 2.80.
• For Return on Networth / Equity (%), as of Mar 25, the value is 18.89. This value is within the healthy range. It has increased from 17.54 (Mar 24) to 18.89, marking an increase of 1.35.
• For Return on Capital Employeed (%), as of Mar 25, the value is 23.14. This value is within the healthy range. It has increased from 20.89 (Mar 24) to 23.14, marking an increase of 2.25.
• For Return On Assets (%), as of Mar 25, the value is 14.46. This value is within the healthy range. It has increased from 11.08 (Mar 24) to 14.46, marking an increase of 3.38.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.14 (Mar 24) to 0.00, marking a decrease of 0.14.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.24 (Mar 24) to 0.00, marking a decrease of 0.24.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.45. It has decreased from 1.48 (Mar 24) to 1.45, marking a decrease of 0.03.
• For Current Ratio (X), as of Mar 25, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.01 (Mar 24) to 3.08, marking an increase of 1.07.
• For Quick Ratio (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has increased from 1.39 (Mar 24) to 1.55, marking an increase of 0.16.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 10.89. This value exceeds the healthy maximum of 8. It has increased from 5.01 (Mar 24) to 10.89, marking an increase of 5.88.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 19.43. This value is below the healthy minimum of 20. It has decreased from 24.46 (Mar 24) to 19.43, marking a decrease of 5.03.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 16.19. This value is below the healthy minimum of 20. It has decreased from 19.65 (Mar 24) to 16.19, marking a decrease of 3.46.
• For Earning Retention Ratio (%), as of Mar 25, the value is 80.57. This value exceeds the healthy maximum of 70. It has increased from 75.54 (Mar 24) to 80.57, marking an increase of 5.03.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 83.81. This value exceeds the healthy maximum of 70. It has increased from 80.35 (Mar 24) to 83.81, marking an increase of 3.46.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 55.73. This value is within the healthy range. It has increased from 13.25 (Mar 24) to 55.73, marking an increase of 42.48.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 32.34. This value is within the healthy range. It has increased from 7.91 (Mar 24) to 32.34, marking an increase of 24.43.
• For Enterprise Value (Cr.), as of Mar 25, the value is 24,894.64. It has increased from 15,411.41 (Mar 24) to 24,894.64, marking an increase of 9,483.23.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.50. This value is within the healthy range. It has increased from 0.85 (Mar 24) to 1.50, marking an increase of 0.65.
• For EV / EBITDA (X), as of Mar 25, the value is 9.22. This value is within the healthy range. It has increased from 6.72 (Mar 24) to 9.22, marking an increase of 2.50.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.51. This value is within the healthy range. It has increased from 0.76 (Mar 24) to 1.51, marking an increase of 0.75.
• For Retention Ratios (%), as of Mar 25, the value is 80.56. This value exceeds the healthy maximum of 70. It has increased from 75.53 (Mar 24) to 80.56, marking an increase of 5.03.
• For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 2.87, marking an increase of 0.99.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.51. This value is within the healthy range. It has increased from 0.76 (Mar 24) to 1.51, marking an increase of 0.75.
• For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 24) to 0.06, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness